ClinicalTrials.gg
RecruitingNCT06922617STEPSUpdated Oct 22, 2026

STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking

An interventional study of Switching to E-Cigarette and Quitting using Medication in Tobacco Use and Substance Use Disorders, sponsored by Medical University of South Carolina. Recruiting at 4 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 22, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.

Planned enrollment
97th of 288
240 · median 120
Started
2025
with 22 others
No phase
233 of 313
40 open now
Primary completion
2028-09
later than 52 of 64 live
Registered
285th of 313
by date
Lead sponsor
9 of 313
Medical University of South Carolina

Among the 313 studies in Tobacco Use with a site in United States, this one is the 97th largest by planned enrollment of the 288 interventional ones that give a count, is one of 23 that started in 2025, is one of 233 with no phase, reaches primary completion later than 52 of the 64 other live ones, and was the 285th registered.

Tobacco Use

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

Browse Tobacco Use studies →

Open to participants now

54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Tobacco Use with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether non-cigarette tobacco products, namely e-cigarettes (nicotine vapes), can help people who smoke and are in treatment for substance use disorder quit smoking by switching completely to e-cigarettes as compared to FDA-approved medications, namely nicotine replacement therapy in the form of patches and lozenges. Participation will last 6 months and includes 14 weekly study visits and 2 follow-up study visits (in-person, but virtual study visits are possible). Participants will also complete a short daily diary on their phones each day for the first twelve weeks. To qualify, participants (ages 21+) must be enrolled in an outpatient substance use disorder (SUD) treatment program. The study is being done in four regions across South Carolina: Charleston, Pickens/Easley, Conway, and Greenville.

Read the detailed description

Tobacco use rates among those with substance use disorders (SUD) are disproportionately high compared to the general population. While rates of tobacco use continue to decline in the general population, use rates among those with SUD have remained stagnant, with only slight declines noted in recent years. Despite this, clients enrolled in SUD treatment rarely engage in evidence-based tobacco treatment and many do not quit using tobacco during treatment. Continued tobacco use during SUD treatment results in worse substance-related treatment outcomes, as well as premature morbidity and mortality. Yet, surprisingly few rigorous randomized controlled trials (RCT) have been conducted to assess tobacco cessation in this population. Strategies to reduce the harmful effects of continued tobacco use in a SUD treatment population are urgently needed.

Importantly, those in SUD treatment who smoke cigarettes endorse an interest in quitting smoking, but quit rates are lower among a SUD population compared to the general population by about half. For example, within our own hospital system at the Medical University of South Carolina (MUSC), which employs an opt-out tobacco cessation approach for all inpatients, those with mental health diagnoses, including SUD, were less likely to report tobacco abstinence at 30-day follow-up post-discharge, compared to those without mental health diagnoses. There is a clear public health need to address the harmful impact of combustible tobacco use among those enrolled in treatment for SUD and ensure that these strategies, should they be efficacious in reducing harm, are acceptable and feasible for SUD clients, program staff and leadership. The need to address combustible tobacco use in this population has been present for decades and yet advances in this area have been minimal. Those in SUD treatment are still disproportionately impacted by the harms of combustible tobacco, which may be due, in large part, to the barriers that exist in treating tobacco as part of SUD standard of care.

Participants will be randomized 1:1 to: 1) switch exclusively to ENDS, or 2) quit tobacco with NRT. The aims of this study are to: 1) evaluate if switching to ENDS leads to greater rates of 7-day biologically confirmed point prevalence abstinence (PPA) from cigarette smoking at 12 weeks compared to quitting with NRT among those enrolled in SUD treatment (Aim 1), 2) evaluate patient, provider, and organizational-level implementation outcomes using mixed methods according to the Proctor framework, which describes barriers and facilitators of successful implementation of an intervention (Aim 2), and 3) assess the impact of switching to ENDS compared to quitting with NRT on SUD treatment outcomes and engagement to test for non-inferiority over 12 weeks (Aim 3).

03

Conditions studied

  • Tobacco Use
  • Substance Use Disorders
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 21+ years of age,
  2. smoke at least 5 cigarettes per day daily or near daily for the past 6 months,
  3. be enrolled in outpatient SUD treatment and have an SUD diagnosis (past or current),
  4. must submit a breath CO sample of ≥ 7 parts per million at screening and a positive instant-read urinary cotinine test,
  5. have had at least one failed smoking quit attempt in their lifetime,
  6. have interest in reducing smoking, quitting smoking, or switching to a less harmful product, and
  7. if female, agrees to use a form of during the study.

Exclusion criteria

Exclusion criteria:

  1. any significant or unstable medical or psychiatric concern that would affect safety,
  2. current use of smoking cessation pharmacotherapy for the purposes of quitting smoking,
  3. pregnant, breastfeeding, or trying to become pregnant,
  4. for NRT, and
  5. currently using an ENDS on 20+ days out of the past 30.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Medication

    This arm includes participants randomly assigned to the medication group. Participants will receive combination nicotine replacement therapy (NRT). The NRT will consist of transdermal patches and nicotine lozenges. Participants will receive study product for 12 weeks.

    Drug: Quitting using Medication · Behavioral: Counseling

  • Experimental
    Switching to an E-Cigarette

    This arm includes participants randomly assigned to the E-Cigarette Group. Participants will receive a study-provided e-cigarette product for 12 weeks.

    Behavioral: Switching to E-Cigarette · Behavioral: Counseling

Interventions

  • BehavioralSwitching to E-Cigarette

    Participants will receive twelve weeks of e-cigarette products with instructions to switch completely at switch date

  • DrugQuitting using Medication

    Participants will receive twelve weeks of FDA approved medication, combination NRT, with instructions to quit smoking cigarettes at quit date

  • BehavioralCounseling

    Participants will recieve brief weekly counseling to support their quit or switch attempt from cigarettes.

06

What researchers measure

Primary outcomes

  1. Abstinence from smoking at end of treatment

    7-day biologically confirmed point prevelance abstinence from cigarette smoking at Week 12 end of treatment visit

    Time frame: 7 days

Secondary outcomes

  1. Acceptability of the intervention

    4-item Acceptability of the Intervention Measure where higher scores indicate greater acceptability (range 1-5)

    Time frame: 12 weeks

  2. Number of negative urine drug screens

    Number of negative urine drug screens (for the primary substance of use) submitted during the 12 week treatment

    Time frame: 12 weeks

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2028, 34 months after the start.

Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 34 months is above that.

Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2028 → Dec 2028, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Dec 1, 2028was Sep 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 1, 2028→Dec 1, 2028
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Study completion Sep 1, 2028→Dec 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06922617
Responsible party
Erin McClure (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Apr 10, 2025
Start date
Oct 17, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Ela Williams
Contact
williela@musc.edu
(843) 876-2090

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion